Conclusion and Recommendation
Basically, Pfizer is a very aggressive pharmaceutical company as you will see that they are the no.1 in sales starting from 2001 and maintain for 2 years up till now. Their strong Resources & Development department focusing the need of the pharmaceutical industry and creating up to date products for today's market. Every topest doctor is willing to use Pfizer's product as it represents they are the leader in the pharmaceutical industry but on the other hand, the price is quite expensive.
As Pfizer is so aggressive, the consumption no matter for hospitals and private doctors has already been over the target of the following years so it is quite difficult to have further growth. If the company keeps on adding target to medical representatives, the outcome would become negative. So, Pfizer is better to slow down their strategic a little bit that to let the outside consumption to be digest first than to make further increment.
Outside competitor like AstraZeneca is following Pfizer's strategic to expand their business. AstraZeneca is very famous in United Kingdom and going to increase the market share in Hong Kong so Pfizer needs to aware this competitor and make necessary arrangements.
…
